Literature DB >> 1341233

DNA ploidy in squamous oesophageal carcinoma.

T N Walsh1, T Dorman, O Droogan, B Curran, D O Hourihane, M Leader, T P Hennessy.   

Abstract

The role of DNA ploidy in the management of oesophageal carcinoma is unclear. Most studies have employed flow cytometry (FC) for DNA analysis but some have used image analysis (IA) of tissue sections. In this study aneuploidy rates in stage IIa squamous tumours were determined by both FC and IA of cell suspensions and results were compared with outcome in two patient subgroups. Group 1 (n = 15) were patients who died from tumour recurrence within 1 year of surgery while Group 2 (n = 21) were patients who survived tumour free for at least 1 year. Aneuploidy rates differed significantly between techniques; 29 of 36 tumours (81%) were aneuploid by IA compared with 19 of 34 (56%) by FC (P < 0.05). Aneuploidy rates differed significantly between groups 1 and 2 as determined by FC (79%) versus 40%) (P < 0.05) but not by IA (93% versus 71%) (P = ns). Euploid status was a good prognostic indicator; 6 of 7 (86%) patients with euploid tumours by IA and 12 of 15 (80%) by FC (P < 0.05) survived more than 1 year. The sensitivity and specificity of euploidy was 93% and 28.6% for IA compared with 78.6% and 60% for FC. Since 33 (92%) of these tumours exhibited a marked peritumoral desmoplastic or chronic inflammatory reaction IA, being more sensitive to subtle nuclear change, may be a more appropriate technique than FC for evaluation of the role of ploidy in such tumours.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1341233     DOI: 10.1016/0960-7404(92)90054-o

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  2 in total

Review 1.  Oesophageal cancer: on the threshold of hope.

Authors:  T N Walsh
Journal:  Ir J Med Sci       Date:  1995 Jul-Sep       Impact factor: 1.568

2.  Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites.

Authors:  K Dolan; J Garde; J Gosney; M Sissons; T Wright; A N Kingsnorth; S J Walker; R Sutton; S J Meltzer; J K Field
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.